US Bancorp DE boosted its stake in shares of Certara, Inc. (NASDAQ:CERT – Free Report) by 2.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,827 shares of the company’s stock after acquiring an additional 640 shares during the quarter. US Bancorp DE’s holdings in Certara were worth $574,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. increased its stake in Certara by 33.3% during the first quarter. Russell Investments Group Ltd. now owns 119,879 shares of the company’s stock worth $2,871,000 after acquiring an additional 29,938 shares during the last quarter. Summit Creek Advisors LLC grew its stake in shares of Certara by 1.1% during the first quarter. Summit Creek Advisors LLC now owns 602,912 shares of the company’s stock valued at $14,536,000 after buying an additional 6,501 shares during the last quarter. Truist Financial Corp grew its stake in shares of Certara by 35.8% during the first quarter. Truist Financial Corp now owns 16,410 shares of the company’s stock valued at $396,000 after buying an additional 4,327 shares during the last quarter. Ranger Investment Management L.P. grew its stake in shares of Certara by 6.5% during the first quarter. Ranger Investment Management L.P. now owns 528,165 shares of the company’s stock valued at $12,734,000 after buying an additional 32,010 shares during the last quarter. Finally, Commerce Bank grew its stake in shares of Certara by 2.2% during the first quarter. Commerce Bank now owns 31,260 shares of the company’s stock valued at $754,000 after buying an additional 673 shares during the last quarter. 67.34% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on CERT shares. Barclays cut their target price on Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, August 11th. Jefferies Financial Group cut Certara from a “buy” rating to a “hold” rating and cut their target price for the company from $24.50 to $17.00 in a research note on Tuesday. William Blair cut Certara from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 10th. Credit Suisse Group lowered their price target on Certara from $27.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, August 10th. Finally, Bank of America lowered their price target on Certara from $27.00 to $24.00 and set a “buy” rating for the company in a report on Tuesday, August 15th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Certara has a consensus rating of “Hold” and a consensus target price of $21.13.
Certara Stock Down 0.7 %
Certara stock opened at $15.89 on Friday. The business has a fifty day moving average of $17.98 and a two-hundred day moving average of $20.19. The company has a quick ratio of 3.43, a current ratio of 3.43 and a debt-to-equity ratio of 0.26. The firm has a market cap of $2.54 billion, a P/E ratio of 132.43, a P/E/G ratio of 1.06 and a beta of 1.42. Certara, Inc. has a twelve month low of $10.60 and a twelve month high of $24.96.
Certara (NASDAQ:CERT – Get Free Report) last posted its earnings results on Wednesday, August 9th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. The company had revenue of $90.45 million during the quarter, compared to analyst estimates of $92.04 million. Certara had a return on equity of 5.56% and a net margin of 5.45%. On average, analysts forecast that Certara, Inc. will post 0.34 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Certara news, insider Patrick F. Smith sold 19,104 shares of the company’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $21.55, for a total transaction of $411,691.20. Following the completion of the sale, the insider now owns 59,975 shares in the company, valued at $1,292,461.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 2.60% of the stock is owned by company insiders.
About Certara
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.
Read More
- Five stocks we like better than Certara
- How to Invest in Marijuana Stocks
- Can These 2 Industrial Titans Extend Double-Digit YTD Growth?
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- How to Profit from These 3 Membership Club Stocks’ Strengths
- How to Invest in Cybersecurity
- 5 Best High-Yield Dividend Stocks for Any Economic Climate
Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERT – Free Report).
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.
